



# SIMPLIFIED DATA MANAGEMENT WITH OMNIPOD DISCOVER™


The official diabetes insights platform for Omnipod® 5 Automated Insulin Delivery System

Ask your Omnipod® Representative for more information on Omnipod Discover™ today!



# EASY TO INTERPRET DATA TO INFORM OMNIPOD 5 OPTIMISATION


## THE OMNIPOD 5 ALGORITHM IN ACTION


 Omnipod 5 data is automatically uploaded into Omnipod Discover and can be accessed at any time to support in-person or remote clinic visits


Omnipod Discover shows how Omnipod 5 helps to proactively correct and protect<sup>1,2</sup>




Auto corrects up to 4x the adaptive rate to help proactively correct highs



 Adjusts every 5 minutes

Decreases and/or pauses insulin delivery to help protect against lows 



Omnipod<sup>®</sup> 5 users receive a weekly email linking to their personalised insights report.


## OMNIPOD 5 USERS GET EFFORTLESS ACCESS TO THEIR DATA



Simple-to-read insights on glucose patterns and insulin trends




Insights help to understand how certain behaviours and pump settings directly affect glucose management

 Omnipod Discover translates diabetes data into actionable insights to empower Omnipod 5 users with their diabetes management

Screens for illustrative purposes only

# EMPOWER YOUR OMNIPOD 5 PATIENTS

## ACTIONABLE DATA INSIGHTS



Screens for illustrative purposes only

For more information please contact your local Omnipod Representative: [omnipod.com/en-au/hcp/contact](https://omnipod.com/en-au/hcp/contact)

### References:

1. Brown S, et al. *Diabetes Care*. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6–70 yrs [adults/adolescents (n=128; aged 14–70 yrs) children (n=112; aged 6–13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time >10 mmol/L in adults/adolescents and children, ST vs. 3-month Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%,  $P<0.0001$ , respectively. Mean time <3.9 mmol/L in adults/adolescents and children, ST vs. 3-month Omnipod 5: 2.9% vs. 1.3%,  $P<0.0001$ ; 2.2% vs. 1.8%,  $P=0.8153$ , respectively. Results measured by CGM. Study funded by Insulet.

2. Sherr JL, et al. *Diabetes Care*. 2022. 45(8):1907–1910. Prospective trial in 80 participants with T1D aged 2–5.9 yrs. Study included a 14-day ST phase followed by a 3-month Omnipod 5 HCL phase. Mean time >10 mmol/L in very young children (2–5.9 yrs) as measured by CGM: ST = 39.4%, 3-month Omnipod 5 = 29.5%,  $P<0.0001$ . Mean time <3.9 mmol/L in very young children (2–5.9 yrs) as measured by CGM: ST = 3.43%, 3-month Omnipod 5 = 2.46%,  $P=0.0204$ . Results measured by CGM. Study funded by Insulet.

The Omnipod® 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older requiring insulin.

Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide and [www.omnipod.com/en-au/important/safety/information](https://www.omnipod.com/en-au/important/safety/information) for complete safety information including indications, contraindications, warnings, cautions, and instructions.

Omnipod Discover™ is a retrospective data analytics and reporting system intended for Omnipod® 5 System users or their caregivers and their healthcare providers for the analysis of glucose and insulin delivery data in home and healthcare settings. It is intended as supplemental data for the users to support diabetes management and aid healthcare providers in patient care. Omnipod Discover™ is not intended for people with diabetes in acute care settings or for real-time patient monitoring. The Omnipod Discover software platform is not intended to replace the primary real-time display of the sensor or insulin delivery data on the device, nor does it control any functions of the Omnipod® 5 System. Any medical treatment decision or adjustments should not be made based on this software platform; a qualified healthcare professional needs to be consulted to make such decisions.